FULC vs. AVDL, BCYC, ZYME, SEPN, NUVB, PSTX, COLL, GYRE, COGT, and AVBP
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Zymeworks (ZYME), Septerna (SEPN), Nuvation Bio (NUVB), Poseida Therapeutics (PSTX), Collegium Pharmaceutical (COLL), Gyre Therapeutics (GYRE), Cogent Biosciences (COGT), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
In the previous week, Avadel Pharmaceuticals had 35 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 37 mentions for Avadel Pharmaceuticals and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.70 beat Avadel Pharmaceuticals' score of 0.03 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.
Fulcrum Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Fulcrum Therapeutics' return on equity of -7.31% beat Avadel Pharmaceuticals' return on equity.
Fulcrum Therapeutics has lower revenue, but higher earnings than Avadel Pharmaceuticals. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals received 248 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 66.28% of users gave Avadel Pharmaceuticals an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote.
Avadel Pharmaceuticals currently has a consensus price target of $21.00, indicating a potential upside of 160.87%. Fulcrum Therapeutics has a consensus price target of $9.33, indicating a potential upside of 129.89%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Fulcrum Therapeutics.
Avadel Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500.
69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 4.8% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Avadel Pharmaceuticals beats Fulcrum Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 1/14/2025 by MarketBeat.com Staff
Free FULC Stock Alerts